论文部分内容阅读
目的观察替米沙坦对高血压患者胰岛素抵抗的影响。方法入选初诊为原发性高血压患者110例为研究对象,同期年龄和性别相匹配的健康体检者100例为对照组。高血压患者给予替米沙坦40～80mg/d,治疗12周。观察高血压患者治疗前后血压、空腹血糖和胰岛素(FINS)、胰岛素敏感指数(ISI)和胰岛素抵抗指数(HOMA-IR)水平的变化。结果治疗前高血压患者血压、FINS和HOMA-IR水平明显高于对照组,ISI水平明显低于对照组(均P<0.05)。替米沙坦治疗12周后,高血压患者的血压明显下降,空腹血糖、FINS和HOMA-IR水平降低,ISI水平升高(均P<0.05)。结论替米沙坦可改善高血压患者的胰岛素抵抗。
Objective To observe the effect of telmisartan on insulin resistance in hypertensive patients. Methods One hundred and ten newly diagnosed patients with essential hypertension were enrolled in this study. One hundred healthy subjects with the same age and gender were selected as the control group. Patients with hypertension were given telmisartan 40 ~ 80mg / d for 12 weeks. To observe the changes of blood pressure, fasting blood glucose and insulin (FINS), insulin sensitivity index (ISI) and insulin resistance index (HOMA-IR) before and after treatment in hypertensive patients. Results Before treatment, the levels of blood pressure, FINS and HOMA-IR in hypertensive patients were significantly higher than those in the control group, and the ISI levels were significantly lower than those in the control group (all P <0.05). After 12 weeks of treatment with telmisartan, the blood pressure of hypertensive patients decreased significantly, while the level of fasting blood glucose, FINS and HOMA-IR decreased and the level of ISI increased (all P <0.05). Conclusion Telmisartan can improve insulin resistance in patients with hypertension.